TABLE 5.

Mortality rates (21 day) in 97 ESBL-BSI patients initially treated with antimicrobial agents to which the infecting organism displayed in vitro susceptibility

Antimicrobial agents administered (n)No. (%) of patientsOR (95% CI)P
Nonsurvivors (n = 18)Survivors (n = 79)
Aminoglycosides (20)5 (27.8)15 (19)1.48 (0.59-3.66)0.40
β-Lactam-β-lactamase inhibitors (33)4 (22.2)29 (36.7)0.55 (0.19-1.55)0.24
Carbapenems (28)1 (5.5)27 (34.2)0.14 (0.02-1.03)0.01
Ciprofloxacin (16)8 (44.4)8 (10.1)4.05 (1.89-8.65)<0.001